Lilly Oncology chief resigns
pharmafile | January 27, 2011 | News story | Research and Development, Sales and Marketing | Eli Lilly, John Johnson, Lilly Oncology, appointment, lilly, research and development, sales and marketing
Lilly has an unexpected search on its hands for someone to lead its oncology business after John Johnson unexpectedly announced he would be stepping down.
Johnson was brought in as president of Lilly Oncology after the company’s 2008 acquisition of ImClone Systems, where he served as chief executive.
“Given his previous post at ImClone, John has played a key role leading the integration efforts since Lilly’s acquisition,” said Lilly chairman, president and chief executive John Lechleiter.
“He has always been a champion of serving patients and has guided the Lilly Oncology pipeline to an all-time high – one of the largest clinical-stage pipelines of potential cancer medicines in the industry.”
Johnson’s resignation is effective from tomorrow and Lilly said a successor would be announced in the coming weeks.
Dominic Tyer
Related Content

Lilly opens fourth US Gateway Labs site
Eli Lilly has opened its newest Lilly Gateway Labs (LGL) site in San Diego, California, …

PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025
The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …

Lilly’s drug for early Alzheimer’s shows promising results
Eli Lilly (Lilly) has announced positive new data from the long-term extension of its phase …






